VIVUS Inc

VIVUS — Investor Presentation (January 2015)

33 slides from VIVUS's investor presentation, Jan 15, 2015

  1. Slide 1: Innovative Therapies Novel Products

    Innovative Therapies Novel Products January 2015 ©2015 VIVUS Inc. All rights reserved www.vivus.com

  2. Slide 2: Forward looking statement

    Forward looking statement This presentation contains "forward-looking" statements that involve risks and uncertainties. These statements typically may be identified by the use of forward-looking words or phrases such as "may," "believe," "expect," "forecast," "intend," "anticipate," "predict," "shou

  3. Slide 3: VIVUS milestones - 2014

    VIVUS milestones - 2014 Qsymia New clinical publications (CV benefit-risk; efficacy in high BMI patients; efficacy in older patients) New market access initiatives (pharmacoeconomic data; formulary positioning) New DTP-oriented initiatives; search engine optimization (SEO) New patents issued and oth

  4. Slide 4: Obesity Market & Qsymia

    Obesity Market & Qsymia 3 ©2015 VIVUS Inc. All rights reserved www.vivus.com

  5. Slide 5: Over 110 million US adults are obese or overweight with a comorbidity

    HTN: 20.0 M HTN2/ Dyslipidemia: 11.4 M HTN/Diabetes/ Dyslipidemia: 21.9 M Diabetes/ Dyslipidemia: 5.0 M Dyslipidemia: 35.0 M HTN/ Diabetes: 2.8 M Diabetes: 1.4 M U.S. Obese and Overweight w/co-morbidity population1 Over 110 million US adults are obese or overweight with a weight-related comorbidity

  6. Slide 6: About Qsymia

    About Qsymia Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related med

  7. Slide 7: Qsymia magnitude of effect

    Qsymia magnitude of effect Pivotal 1-Year Studies: Weight Loss Over Time (Observed/ITT Data) 6 Study 1 (EQUIP1) Study 2 (CONQUER2) Time (Week) Time (Week) 56 ITT-LOCF 56 ITT-LOCF All observed data; *p<0.0001 vs placebo; ‡p<0.0001 vs. Qsymia Mid or Low The most commonly observed side effects in contr

  8. Slide 8: Qsymia consistency of effect

    Qsymia consistency of effect 7 *Dvorak, R., Peterson, C., Day, W. Application of Proposed Treatment Algorithm (PTA) Improves the Benefit/Risk Profile of Phentermine Plus Extended-Release Topiramate (PHEN/TPM ER) Presented at The Obesity Society 30th Annual Scientific Meeting, Sep-2012 - San Antonio;

  9. Slide 9: Beneficial effects of weight loss with Qsymia

    BENEFICIAL EFFECTS of WEIGHT LOSS WITH Qsymia 8 Diastolic BP Systolic BP Fibrinogen Triglycerides TChol:HDL IWQOL total Fasting glucose HOMA-IR Fasting insulin HbA1c hs-CRP ALT Apnea Hypopnea Index Placebo subtracted effect size Placebo subtracted effect size Favors Qsymia Favors Placebo Favors Qsym

  10. Slide 10: Clinical Publications support the benefit-risk profile of Qsymia

    Clinical Publications support the benefit-risk profile of Qsymia “Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended-Release.” W. Timothy Garvey, MD, et al. Diabetes Care1 Patients on Recommended (7.5/46) and Top (15/92)

  11. Slide 11: Obesity Treatment Evolution

    Obesity Treatment Evolution 10 ©2015 VIVUS Inc. All rights reserved www.vivus.com

  12. Slide 12: AACE Treatment algorithm: Medical Therapy is Recommended

    AACE Treatment algorithm: Medical Therapy is Recommended 11 Obesity management and FDA-approved anti-obesity medications now recommended for: Prediabetes Diabetes Dyslipidemia Hypertension 1st ever inclusion of drug therapy in treatment algorithm Primary Care Physicians refer to AACE algorithm ©2015

  13. Slide 13: Greater recognition of obesity as a disease, pharmacotherapy as a treatment option

    Greater recognition of obesity as a disease, pharmacotherapy as a treatment option Obesity is now recognized as a disease by the leading medical association in the U.S. AMA recognition is important support for policy makers, healthcare providers and payors Additional recent publications support long

  14. Slide 14: Qsymia Commercialization

    Qsymia Commercialization 13 ©2015 VIVUS Inc. All rights reserved www.vivus.com

  15. Slide 15: Healthcare provider targeting

    Healthcare provider targeting Ongoing deployment optimization includes Prioritizing targets based on prescribing behavior and other factors Analyzing and redefining territories Reconfiguring and redeploying sales resources against highest value targets Core Message: Qsymia delivers 5X the weight los

  16. Slide 16: Healthcare provider engagement

    Healthcare provider engagement Ongoing education process (guidelines; clinical data) Focus for new starts on high-need patient (BMI>35) Provides an avenue for Qsymia trial and adoption Maintain Free Trial Offer (14 days of Starting Dose) Works as a two-week sample; lowers out-of-pocket $ for patient

  17. Slide 17: Patient engagement

    patient engagement Ongoing DTP Outreach and Dialog Lapsed patients Treatment failures Treatment naïve patients Emphasis on Communities of Patients 16 ©2015 VIVUS Inc. All rights reserved www.vivus.com

  18. Slide 18: Qsymia monthly TRx volume remained steady since Oct-2013

    Source: IMS (Monthly) Qsymia monthly TRx volume remained steady since Oct-2013; anti-obesity market trxs grew 17 ©2015 VIVUS Inc. All rights reserved www.vivus.com MAT (000) AO Market TRxs Branded AO TRx Nov-2012 7,993 276 Nov-2013 8,432 (+5.5%) 613 (+122%) Nov-2014 9,270 (+10%) 1,227 (+100%) 39.0 3

  19. Slide 19: Qsymia experience since launch

    ~51,000 Prescribers ~300,000 Patients ~900,000 Prescriptions Source: VIVUS Data Warehouse (PR) Qsymia experience since launch (through nov-2014) ©2015 VIVUS Inc. All rights reserved www.vivus.com 18

  20. Slide 20: Qsymia TRxs by specialty

    Spec CARD ENDO NP/PA OB/GYN PCP SURG Avg Rx/MD 13.0 38.7 8.3 12.5 12.1 9.2 Source: VIVUS Data on File, includes MO+PR Retail Qsymia trxs by Specialty – YTD nov-2014 Endo is the leading specialty by productivity ©2015 VIVUS Inc. All rights reserved www.vivus.com 19 CARD 1% ENDO 5% NP/PA 18% OB/GYN 4%

  21. Slide 21: Qsymia coverage is steady

    Qsymia coverage is steady Q4 2013 2014 20 ©2015 VIVUS Inc. All rights reserved www.vivus.com 38% 38% 43% 43% 44% 44% 44% 46% 46% 48% 48% 48% 48% 48% % Access

  22. Slide 22: Qsymia pharmacoeconomics supported in the literature

    Qsymia pharmacoeconomics supported in the literature Finkelstein, E. A. and Kruger, E. (2014), Meta- and cost-effectiveness analysis of commercial weight loss strategies. Obesity, 22: 1942–1951. doi: 10.1002/oby.20824 Study conducted by researchers at Duke-National University of Singapore (NUS) Grad

  23. Slide 23: Qsymia has exclusive formulary position with CVS/Caremark

    Qsymia has exclusive formulary position with cvs/caremark Qsymia is the sole antiobesity agent listed on the CVS/Caremark Performance Drug List Preferred brand (Tier 2) that is clinically appropriate in an antiobesity class ©2015 VIVUS Inc. All rights reserved www.vivus.com 22

  24. Slide 24: OPM Endorses use of Anti-Obesity Medications for Federal Employees

    OPM Endorses use of Anti-Obesity Medications for Federal Employees (Mar-2014) OPM=Office of Personnel Management 23 ©2015 VIVUS Inc. All rights reserved www.vivus.com

  25. Slide 25: Qsiva CVOT Qsymia IP

    Qsiva CVOT Qsymia IP 24 ©2015 VIVUS Inc. All rights reserved www.vivus.com

  26. Slide 26: Qsiva European strategy

    Qsiva European strategy Goal Satisfy FDA post-approval requirements with a single CVOT (AQCLAIM/OB-401) that may also support EU registration Strategy Create interim analysis CVOT so that ~two years of data may be used to support an application while trial continues Tactics/Implementation Dialog ong

  27. Slide 27: AQCLAIM study (CVOT)

    Aqclaim study (CVOT) A Qsymia® CardiovascuLAr morbIdity and Mortality (AQCLAIM) Study in Subjects with Documented Cardiovascular Disease Primary Efficacy Endpoint: Time to 1st occurrence of nonfatal MI, nonfatal stroke or CV death Number of Subjects: ~11,000 – 16,000 Number of Sites: ~450 (North Ame

  28. Slide 28: New patents extend Qsymia coverage to 2029

    New patents extend qsymia coverage to 2029; acquisition of additional patents removes uncertainty Four additional VIVUS patents with claims covering QSYMIA issued in 2013 and 2014, extending coverage by up to nine years U.S. Patent Nos. 8,580,298 and 8,895,058 26 and 32 claims, respectively, directe

  29. Slide 29: Stendra Prescribing information

    Stendra Prescribing information About STENDRA™ STENDRA is a prescription medicine used to treat erectile dysfunction (ED). STENDRA (avanafil) is licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS has development and commercial rights to STENDRA for the treatment of sexual dysfunction worldwid

  30. Slide 30: Avanafil partnerships / update

    avanafil partnerships / update Auxilium Pharmaceuticals, Inc. - U.S. & Canada U.S. launched 15-minute onset-of-action claim incorporated into STENDRA label (Sep-2014) Menarini - 40 Countries in Europe + AUS/NZ EU-5 launched; SPEDRA available in 23 countries within Menarini territory 15-minute onset-

  31. Slide 31: Financial Update

    Financial Update 30 ©2015 VIVUS Inc. All rights reserved www.vivus.com

  32. Slide 32: VIVUS, Inc. cash and net revenue

    VIVUS, Inc. Cash, Cash equivalents & Available-for-sale securities as of 30-Sep-2014: $306.9MM; as of 31-Dec-2013: $343.3MM ©2015 VIVUS Inc. All rights reserved www.vivus.com 31 YTD 30-Sep ($MM) 2014 2013 Net Revenue ($MM) Total Total Qsymia – Net product revenue $32.6 $16.0 STENDRA/SPEDRA – License

  33. Slide 33: Innovative Therapies Novel Products

    Innovative Therapies Novel Products January 2015 ©2015 VIVUS Inc. All rights reserved www.vivus.com

Vivus — Investor Presentation (January 2015) on 6ix